Senseonics (NYSE:SENS) Shares Gap Down – What’s Next?

Senseonics Holdings, Inc. (NYSE:SENS) gapped down prior to trading on Monday . The stock had previously closed at $0.96, but opened at $0.84. Senseonics shares last traded at $0.90, with a volume of 5,892,521 shares.

Analyst Ratings Changes

Several analysts have recently commented on the stock. StockNews.com started coverage on shares of Senseonics in a research note on Thursday, December 26th. They set a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Stock Up 2.8 %

The business has a 50 day moving average of $0.60 and a 200 day moving average of $0.45. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Senseonics (NYSE:SENS) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). The firm had revenue of $4.26 million during the quarter, compared to analyst estimates of $4.02 million. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. As a group, equities research analysts anticipate that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current fiscal year.

Insider Activity

In other Senseonics news, CEO Timothy T. Goodnow acquired 315,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were acquired at an average price of $0.31 per share, with a total value of $97,650.00. Following the completion of the transaction, the chief executive officer now directly owns 11,310,355 shares in the company, valued at $3,506,210.05. This trade represents a 2.86 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the purchase, the chief financial officer now directly owns 2,478,844 shares in the company, valued at approximately $941,960.72. The trade was a 5.31 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Institutional Trading of Senseonics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares during the last quarter. Symmetry Partners LLC acquired a new stake in shares of Senseonics during the 3rd quarter worth about $164,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after buying an additional 85,501 shares during the period. GSA Capital Partners LLP acquired a new position in Senseonics in the 3rd quarter valued at about $117,000. Finally, FMR LLC raised its holdings in Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after acquiring an additional 167,970 shares during the period. 12.36% of the stock is owned by institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.